EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudieOpen Access · CC BY 4.0

Combined SGLT2i and GLP1ra therapy reduces all-cause mortality in people with diabetes, with greater benefit in women

David Garcia-Vega, Sergio Cinza-Sanjurjo, Carlos Tilves-Bellas, Sonia Eiras, José Ramón González-Juanatey

Nutrition, Metabolism and Cardiovascular Diseases · 2025

DOI: 10.1016/j.numecd.2025.104483 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Nutrition, Metabolism and Cardiovascular Diseases, 2025. Verfasst von David Garcia-Vega und 4 weiteren Autor:innen. Beteiligte Einrichtung: University of Santiago de Compostela, Spain; Cardiology Department, Clinical Hospital of Santiago de Compostela, Spain; Centro de Investigación en Re…. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Incretins. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidade de Santiago de Compostela, Government of Galicia Department of Education Science Universities and Professional Training, Instituto de Investigación Sanitaria de Santiago de Compostela.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND AIMS: Combined therapy, sodium-glucose cotransporter 2 inhibitors (SGLT2i), and glucagon-like peptide-1 receptor agonists (GLP1ra) reduce all-cause mortality in patients with diabetes. We aimed to analyse the differential behaviour of combined therapy between women and men regarding all-cause mortality. METHODS AND RESULTS: This is a retrospective observational cohort study. Using "Big data" according to electronic medical records in the Santiago-Barbanza health area, which covers 450,000 patients. Out of 15,118 patients, 41 % were women. The median follow-up was 33 months. Women were older (71 [62-78] vs. 67 [59-75], p:

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsDiabetes Mellitus, Type 2IncretinsHumansFemaleMaleRetrospective StudiesAgedMiddle AgedSex FactorsTreatment OutcomeRisk FactorsTime FactorsRisk AssessmentDrug Therapy, CombinationCause of DeathSpainBiomarkersGlucagon-Like Peptide-1 Receptor

Stichwörter der Autor:innen

Cardiovascular diseaseDiabetesGLP1raSGLT2i

Substanzen

Sodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsIncretinsGLP1R protein, humanBiomarkersGlucagon-Like Peptide-1 Receptor

Autor:innen und Institutionen

  • University of Santiago de Compostela, Spain; Cardiology Department, Clinical Hospital of Santiago de Compostela, Spain; Centro de Investigación en Red en Enfermedades Cardiovasculares, Spain. Electronic address: david.g…
  • Centro de Investigación en Red en Enfermedades Cardiovasculares, Spain; Centro de Salud de Milladoiro-Ames, Área Sanitaria de Santiago de Compostela, Spain.
  • Cardiology Department, Clinical Hospital of Santiago de Compostela, Spain.
  • Centro de Investigación en Red en Enfermedades Cardiovasculares, Spain; Traslational Cardiology Group, Health Research Institute of Santiago de Compostela, Spain.
  • University of Santiago de Compostela, Spain; Cardiology Department, Clinical Hospital of Santiago de Compostela, Spain; Centro de Investigación en Red en Enfermedades Cardiovasculares, Spain; Traslational Cardiology Gro…

Förderung

  • Universidade de Santiago de Compostela
  • Government of Galicia Department of Education Science Universities and Professional Training
  • Instituto de Investigación Sanitaria de Santiago de Compostela
  • Fundación Instituto de Investigación Sanitaria de Santiago de Compostela

Zitieren

APA

Garcia-Vega, D., Cinza-Sanjurjo, S., Tilves-Bellas, C., Eiras, S., & González-Juanatey, J. R. (2025). Combined SGLT2i and GLP1ra therapy reduces all-cause mortality in people with diabetes, with greater benefit in women. Nutrition, Metabolism and Cardiovascular Diseases. https://doi.org/10.1016/j.numecd.2025.104483

Vancouver

Garcia-Vega D, Cinza-Sanjurjo S, Tilves-Bellas C, Eiras S, González-Juanatey JR. Combined SGLT2i and GLP1ra therapy reduces all-cause mortality in people with diabetes, with greater benefit in women. Nutrition, Metabolism and Cardiovascular Diseases. 2025. doi:10.1016/j.numecd.2025.104483

BibTeX
@article{GarciaVega2025,
  author = {Garcia-Vega, David and Cinza-Sanjurjo, Sergio and Tilves-Bellas, Carlos and Eiras, Sonia and González-Juanatey, José Ramón},
  title = {Combined SGLT2i and GLP1ra therapy reduces all-cause mortality in people with diabetes, with greater benefit in women},
  journal = {Nutrition, Metabolism and Cardiovascular Diseases},
  year = {2025},
  doi = {10.1016/j.numecd.2025.104483}
}
Kostenlos starten →